Revvity agrees to acquire Human Cell Design in metabolic disease research push
RVTY•Revvity to buy Human Cell Design
Revvity entered a definitive agreement to buy France-based Human Cell Design, adding human pancreatic beta cell models for metabolic disease drug discovery.
The deal targets diabetes and obesity research, supporting screening and preclinical work tied to GLP-1 and other metabolic therapies.
Closing is expected in Q4 2026, subject to customary conditions and required approvals.
Financial terms were not disclosed.
